<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5610">
  <stage>Registered</stage>
  <submitdate>25/01/2012</submitdate>
  <approvaldate>25/01/2012</approvaldate>
  <nctid>NCT01520506</nctid>
  <trial_identification>
    <studytitle>Rapid Renal Sympathetic Denervation for Resistant Hypertension</studytitle>
    <scientifictitle>Rapid Renal Sympathetic Denervation for Resistant Hypertension Using the OneShot Ablation System</scientifictitle>
    <utrn />
    <trialacronym>RAPID</trialacronym>
    <secondaryid>CIP 012</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hypertension, Resistant to Conventional Therapy</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Hypertension</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Covidien OneShot System

Experimental: Rapid Renal Denervation - 


Treatment: devices: Covidien OneShot System
Placed percutaneously, the OneShot balloon catheter is advanced into the renal artery using a routine femoral approach in a cardiac catheterization laboratory setting. RF is applied with pre-programmed time and intensity in each of the renal arteries.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Acute Procedural Safety - Acute Procedural Safety, defined as the overall rate of Serious Adverse Events (SAE's) and adverse device effects at discharge:
SAE's related to groin and vascular access complications, and
SAE's related to renal artery injury.</outcome>
      <timepoint>One Week</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Chronic Procedural Safety - Chronic Procedural Safety, defined as the overall rate of Serious Adverse Events and Adverse Device Effects at 6 months</outcome>
      <timepoint>6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Renal Denervation Procedure Effectiveness - Procedural Effectiveness, defined as rate of Office Systolic Blood Pressure (SBP) reduction &gt; 10 mmHg at 6 months compared to baseline</outcome>
      <timepoint>From baseline to 6 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Systolic blood pressure = 160 mmHg despite treatment with a regimen of 3 or more
             anti-hypertensive medications that includes a diuretic and that has been stable for 2
             weeks prior to screening.

          2. Age 18-85 years.

          3. Able to provide informed consent and comply with follow-up visits.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Diameter of left or right renal artery less than 4 mm or greater than 7mm.

          2. Length of target segment of left or right renal artery less than 20mm.

          3. Other renal arterial abnormalities including severe renal artery stenosis, previous
             renal stenting or angioplasty.

          4. End-stage renal disease requiring dialysis or renal transplant.

          5. estimated Glomerular Filtration Rate &lt; 45 mL/min per 1.73 m2.

          6. Type 1 diabetes mellitus.

          7. Myocardial infarction, unstable angina, or cerebrovascular events within 6 months
             prior to screening.

          8. Severe valvular heart disease for which reduction of blood pressure would be
             considered hazardous.

          9. Bleeding disorder or refusing blood transfusions.

         10. Pregnancy or breast feeding.

         11. Peripheral vascular disease precluding catheter insertion.

         12. Any serious medical condition, which in the opinion of the investigator, may adversely
             affect the safety or effectiveness of the participant or the study.

         13. Current enrollment in another investigational drug or device Study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>50</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/06/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Antwerp</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Genk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bonn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Heidelberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>MÃ¼nster</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Luxembourg</country>
      <state>Luxembourg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Eindhoven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Nieuwegein</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Utrecht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Medtronic Endovascular</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Medtronic - MITG</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Meditrial Europe Ltd.</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The Covidien OneShot ablation system use is to deliver low-level radio frequency (RF) energy
      through the wall of the renal artery to denervate the human kidney.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01520506</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>W.A.L. Tonino, MD</name>
      <address>Department of Cardiology, Catherina Hospital, Eindhoven, The Netherlands</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>